| Literature DB >> 30127003 |
Te-Chen Tzeng1, Yuto Hasegawa2,3, Risa Iguchi2,3,4, Amy Cheung2,3, Daniel R Caffrey1, Elizabeth Jeanne Thatcher1, Wenjie Mao2,3, Gail Germain1, Nelsy DePaula Tamburro1, Shigeo Okabe4, Michael T Heneka1,5, Eicke Latz1,5, Kensuke Futai6,3, Douglas T Golenbock7.
Abstract
Alzheimer's disease (AD) is characterized by the progressive destruction and dysfunction of central neurons. AD patients commonly have unprovoked seizures compared with age-matched controls. Amyloid peptide-related inflammation is thought to be an important aspect of AD pathogenesis. We previously reported that NLRP3 inflammasome KO mice, when bred into APPswe/PS1ΔE9 (APP/PS1) mice, are completely protected from amyloid-induced AD-like disease, presumably because they cannot produce mature IL1β or IL18. To test the role of IL18, we bred IL18KO mice with APP/PS1 mice. Surprisingly, IL18KO/APP/PS1 mice developed a lethal seizure disorder that was completely reversed by the anticonvulsant levetiracetam. IL18-deficient AD mice showed a lower threshold in chemically induced seizures and a selective increase in gene expression related to increased neuronal activity. IL18-deficient AD mice exhibited increased excitatory synaptic proteins, spine density, and basal excitatory synaptic transmission that contributed to seizure activity. This study identifies a role for IL18 in suppressing aberrant neuronal transmission in AD.Entities:
Keywords: Alzheimer’s disease; IL18; inflammasome; neuroinflammation; seizures
Mesh:
Substances:
Year: 2018 PMID: 30127003 PMCID: PMC6130368 DOI: 10.1073/pnas.1801802115
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205